D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 103 Citations 46,875 672 World Ranking 3333 National Ranking 83

Overview

What is she best known for?

The fields of study she is best known for:

  • Internal medicine
  • Cancer
  • Surgery

Michele Cavo mainly investigates Multiple myeloma, Internal medicine, Surgery, Transplantation and Bortezomib. Her work in Multiple myeloma tackles topics such as Dexamethasone which are related to areas like Aspirin. Michele Cavo combines subjects such as Gastroenterology, Stem cell and Oncology with her study of Internal medicine.

Her Surgery research focuses on subjects like Urology, which are linked to Creatinine. Her work is dedicated to discovering how Transplantation, Bone marrow are connected with Radiology and other disciplines. Her research integrates issues of Proteasome inhibitor, Refractory, Intention-to-treat analysis, Standard treatment and Pharmacology in her study of Bortezomib.

Her most cited work include:

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group (718 citations)

What are the main themes of her work throughout her whole career to date?

Her primary scientific interests are in Internal medicine, Multiple myeloma, Oncology, Surgery and Transplantation. Her Internal medicine study frequently draws parallels with other fields, such as Gastroenterology. Her studies examine the connections between Multiple myeloma and genetics, as well as such issues in Bone marrow, with regards to Cancer research.

Her work carried out in the field of Oncology brings together such families of science as Relapsed refractory, Clinical trial, Immunology and Daratumumab. Many of her studies on Surgery involve topics that are commonly interrelated, such as Urology. Her Thalidomide research includes elements of Regimen and Autologous transplantation.

She most often published in these fields:

  • Internal medicine (59.70%)
  • Multiple myeloma (54.45%)
  • Oncology (31.30%)

What were the highlights of her more recent work (between 2018-2021)?

  • Internal medicine (59.70%)
  • Multiple myeloma (54.45%)
  • Oncology (31.30%)

In recent papers she was focusing on the following fields of study:

Michele Cavo mostly deals with Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Cancer research. Her work on Bortezomib, Lenalidomide and Daratumumab as part of general Internal medicine study is frequently linked to In patient, bridging the gap between disciplines. Her Bortezomib study also includes

  • Venetoclax that connect with fields like Placebo,
  • Autologous stem-cell transplantation most often made with reference to Regimen.

Her research in Multiple myeloma intersects with topics in Newly diagnosed, Progression-free survival and Transplantation. Her Oncology research is multidisciplinary, incorporating elements of Relapsed refractory, Refractory, Adverse effect, Refractory Multiple Myeloma and Subgroup analysis. Her Cancer research research is multidisciplinary, incorporating perspectives in Aurora Kinase A, Leukemia, Stem cell and Immune system.

Between 2018 and 2021, her most popular works were:

  • Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (136 citations)
  • Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial (93 citations)
  • International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders (91 citations)

In her most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

Her primary areas of investigation include Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Lenalidomide. Her research brings together the fields of Gastroenterology and Internal medicine. Her Multiple myeloma research incorporates elements of Newly diagnosed, Transplantation, Phases of clinical research and Minimal residual disease.

The Oncology study combines topics in areas such as Clinical trial, Gene mutation, Risk stratification, Univariate analysis and Prospective cohort study. In the subject of general Dexamethasone, her work in Isatuximab and Refractory Multiple Myeloma is often linked to In patient, thereby combining diverse domains of study. As part of the same scientific family, Michele Cavo usually focuses on Lenalidomide, concentrating on Survival rate and intersecting with Pembrolizumab, Transient elastography and Complication.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

2775 Citations

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)

1144 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1131 Citations

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Michele Cavo;Paola Tacchetti;Francesca Patriarca;Maria Teresa Petrucci.
The Lancet (2010)

1052 Citations

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Leukemia (2009)

866 Citations

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson.
Leukemia (2008)

861 Citations

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau;Tamás Masszi;Norbert Grzasko;Nizar J Bahlis.
The New England Journal of Medicine (2016)

844 Citations

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Antonio Palumbo;Roman Hajek;Michel Delforge;Martin Kropff.
The New England Journal of Medicine (2012)

801 Citations

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy.
Lancet Oncology (2013)

788 Citations

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Lotfi Benboubker;Meletios Athanasios Dimopoulos;Angela Dispenzieri;John Catalano.
The New England Journal of Medicine (2014)

707 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Michele Cavo

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 285

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 266

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 230

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 217

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 209

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 208

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 204

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 191

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 184

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 183

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 164

Sagar Lonial

Sagar Lonial

Emory University

Publications: 152

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Publications: 150

Martha Q. Lacy

Martha Q. Lacy

Mayo Clinic

Publications: 146

Pieter Sonneveld

Pieter Sonneveld

Erasmus University Rotterdam

Publications: 145

Gareth J. Morgan

Gareth J. Morgan

New York University

Publications: 143

Something went wrong. Please try again later.